Abstract:Ruthenium (III) anticancer candidates have been synthesized and characterized experimentally and theoretically. Their binding affinity toward biomacromolecules, in vitro anticancer activity, apoptosis, cell cycle and gene expression, and molecular docking have been explored. Ruthenium (III) complexes (1–3) of 2‐aminopyrazine (pyz) with general formula of [Hpyz][RuCl4(DMSO)(pyz)](1), Na[RuCl4(pyz)(DMSO)] (2), and (Hpyz)[RuCl4(pyz)2].2H2O (3) have been synthesized and characterized by elemental analyses, FTIR, 1H NMR, and UV–visible spectroscopy, along with the magnetic susceptibility and cyclic voltammetry measurements. The molecular structures of the complexes have also been optimized using density functional theory (DFT) calculation which demonstrates an octahedral geometry to be adopted by the Ru(III) ion. The UV–visible and fluorescence spectra were employed to study the interaction of the compounds with nucleic acid (ctDNA and tRNA) and bovine serum albumin (BSA). The data showed a higher tendency for the ligand and its complexes (1–3) to interact with biomolecules (1 > 2 > 3). All complexes showed potent in vitro anticancer activity against three human cancer cell lines and high safety against normal cell lines as complex (1) is the most active one, it was selected for the flow cytometric evaluation for cell death mode, cell cycle analysis, and matrix metalloproteinase‐9 (MMP9) expression in treated MDA‐231 cells. Proliferating cell nuclear antigen (PCNA) expression and VEGF concentration were evaluated in the treated cells and compared with the untreated ones. Our study proved that complex (1) arrests the cell cycle, inhibits DNA transcription, reduces both MMP9 (validated by our molecular docking investigation targeting MMP9 protein) and PCNA expressions, and induces apoptotic cell death, leading to cancer metastasis prevention.

Structures and Anticancer Activities of a Series of Isomeric Complexes Ru(azpy)2Cl2

Electronic Structures and SARs of the Isomeric Complexes Α-, Β-, Γ- [ru(mazpy)2cl2] with Different Antitumor Activities

Binding to Dna Purine Base and Structure-Activity Relationship of A Series of Structurally Related Ru(Ii) Antitumor Complexes: A Theoretical Study

Synthesis, Antitumor Activity and Structure–activity Relationships of a Series of Ru(II) Complexes

Electronic Structures And Anti-Cancer Activities Of [Ru(Bpy)(2)L](2+), [Ru(Phen)(2)L](2+) (L = Pytp, Pztp)

Synthesis, Characterization and Biological Evaluation of Labile Intercalative Ruthenium(ii) Complexes for Anticancer Drug Screening.

Synthesis, Structural Characteristics, DNA Binding Properties and Cytotoxicity Studies of a Series of Ru(III) Complexes

Novel Polypyridyl Ruthenium Complexes Acting As High Affinity DNA Intercalators, Potent Transcription Inhibitors and Antitumor Reagents.

Synthesis and characterization of novel Ru(III) complexes of 2‐aminopyrazine: Interaction with biomolecules, antineoplastic activity, and computational investigation

Synthesis, characterization and antitumor activity of a series of polypyridyl complexes.

Differences in Structure, Physiological Stability, Electrochemistry, Cytotoxicity, Dna and Protein Binding Properties Between Two Ru(Iii) Complexes

Ru(II)‐Nitrophenylhydrazine/Chlorophenylhydrazine Complexes: Nanoarchitectonics, Biological Evaluation and In silico Study

Synthesis, structures, antiproliferative activity of a series of ruthenium(II) arene derivatives of thiosemicarbazones ligands

Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest

Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor.

Dna/Protein Binding, Molecular Docking, And In Vitro Anticancer Activity Of Some Thioether-Dipyrrinato Complexes

Potent half-sandwich Ru(II) N^N (aryl-BIAN) complexes: Lysosome-mediated apoptosis, in vitro and in vivo anticancer activities

Electronic Structures, DNA-binding, SAR, and Spectral Properties of Ruthenium Methylimidazole Complexes [ru(meim)4l]2+ (l=iip, Tip, 2Ntz)

Potent Half-Sandwich Ru(Ⅱ) N^N (Aryl-Bian) Complexes: Lysosome-mediated Apoptosis, in Vitro and in Vivo Anticancer Activities

Novel Dinuclear Arene Ruthenium(ii) Complexes: Synthesis, Structure, Anticancer Activity and Interaction with DNA

Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation.